CGM technology, which allows diabetes patients to track their blood glucose levels efficiently throughout the day, has been linked with better outcomes. As clinical evidence has piled up, third-party ...
Hosted on MSN
DexCom reiterates $5.16B-$5.25B 2026 revenue outlook while raising operating margin to 23%-23.5%
DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter revenue growth of 15% ...
A list of domestic and international medical and healthcare news for the past week, along with brief commentary. On October ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...
DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program ...
Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results